非酒精性脂肪性肝病的规范化管理*

doi:10.3969/j.issn.1672-5069.2023.04.001

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (4): 457-459.doi: 10.3969/j.issn.1672-5069.2023.04.001

• 述评 • 下一篇

非酒精性脂肪性肝病的规范化管理^*

顾棨, 芮法娟, 倪文婧, 陈倩倩, 吴超, 施军平, 李婕

210008 南京市南京大学医学院附属鼓楼医院感染性疾病科(顾棨,芮法娟,倪文婧,陈倩倩,吴超,李婕);杭州师范大学附属医院肝病科(施军平)

收稿日期:2023-05-07 出版日期:2023-07-10 发布日期:2023-07-21
通讯作者: 李婕,E-mail:lijier@sina.com
作者简介:顾棨,男,24岁,博士研究生。E-mail:602022350060@smail.nju.edu.cn
基金资助:
^*国家自然科学基金面上项目(编号:819705457/82170609);山东省自然科学基金重点项目(编号:ZR2020KH006);济南市科技发展计划项目(编号:202019079)

Chronic disease management in patients with nonalcoholic fatty liver diseases

Gu Qi, Rui Fajuan, Ni Qianqian, et al

Department of Infectious Diseases, Gulou Hospital, Affiliated to Nanjing University School of Medicine, Nanjing 210008, Jiangsu Province, China

Received:2023-05-07 Online:2023-07-10 Published:2023-07-21

摘要/Abstract

关键词: 非酒精性脂肪性肝病, 多学科诊疗, 慢病管理

Key words: Nonalcoholic fatty liver diseases, Multi-disciplinary team, Chronic disease management

顾棨, 芮法娟, 倪文婧, 陈倩倩, 吴超, 施军平, 李婕. 非酒精性脂肪性肝病的规范化管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 457-459.

Gu Qi, Rui Fajuan, Ni Qianqian, et al. Chronic disease management in patients with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(4): 457-459.

[1] Le M H, Yeo Y H, Li X, et al. 2019 global NAFLD prevalence: A systematic review and Meta-analysis. Clin Gastroenterol Hepatol, 2022, 20(12): 2809-17,e28.
[2] Li J, Zou B, Yeo Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and Meta-analysis. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
[3] Sanyal A J, van Natta M L, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med, 2021, 385(17): 1559-1569.
[4] Adams L A, Aantee Q M, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases . Gut, 2017, 66(6): 1138-1153.
[5] Kanwal F, Kramer J R, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease . Hepatology, 2020, 71(3): 808-819.
[6] Zhou Y Y, Zhou X D, Wu S J, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol, 2018, 30(6): 631-636.
[7] Kanwal F, Shubrook J H, Adams L A, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology, 2021, 161(5): 1657-1669.
[8] Unalp-Arida A, Ruhl C E. Liver fibrosis scores predict liver disease mortality in the United States population . Hepatology, 2017, 66(1): 84-95.
[9] Siddiqui M S, Vuppalanchi R, van Natta M L, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019, 17(1): 156-163,e2.
[10] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD) . Endocr Pract, 2022, 28(5): 528-562.
[11] Chalmers J, Wilkes E, Harris R, et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community . Frontline Gastroenterol, 2020, 11(2): 86-92.
[12] Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease . J Hepatol, 2019, 71(2): 371-378.
[13] Mantovani A, Byrne C D, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A Meta-analysis. Diabetes Care, 2018, 41(2): 372-382.
[14] Bonnet F, Gastaldelli A, Pihan-Le Bars F, et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens, 2017, 35(3): 493-500.
[15] Lau K, Lorbeer R, Haring R, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens, 2010, 28(9): 1829-1835.
[16] Lazarus J V, Mark H E, Aantee Q M, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 60-78.

非酒精性脂肪性肝病的规范化管理^*

Chronic disease management in patients with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何方平. 我国NAFLD慢病管理实践现状和建议[J]. 实用肝脏病杂志, 2023, 26(4): 460-462.
[2]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.
[3]	尹会芬, 于红艳, 刘志平. 非酒精性脂肪性肝病合并2型糖尿病患者血清瘦素、视黄醇结合蛋白4和胆碱酯酶水平变化及其临床意义研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 500-503.
[4]	方山山, 杜明桥, 王玥. 垂体功能减退症患者非酒精性脂肪性肝病发生情况及其相关激素水平变化^*[J]. 实用肝脏病杂志, 2023, 26(4): 504-507.
[5]	邱丽瑛, 王迎春. 非酒精性脂肪性肝病与肠道微生态[J]. 实用肝脏病杂志, 2023, 26(3): 308-312.
[6]	湛栖睿, 段太美, 闫洁. 非酒精性脂肪性肝病患者血清淀粉样蛋白A、血浆血红素氧合酶1和骨形成蛋白9水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 348-351.
[7]	赵玲玲, 王贝贝, 姚勇利, 郑有花, 李亚楠. T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 356-359.
[8]	黄慧, 林敏, 曾桂香. 肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征^*[J]. 实用肝脏病杂志, 2023, 26(3): 364-367.
[9]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[10]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[11]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[12]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[13]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[14]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[15]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.